Charging Into the Minefield of Genes and Racial Difference
By Arthur Allen,
The New York Times
| 05. 15. 2014
Few areas of science have contributed more to human misery than the study of racial difference. In the 1920s, eugenicists from top American universities promoted the sterilization of the unfit and later praised Hitler’s racial codes while advocating laws that would exclude thousands of Jews from our shores.
Contemporary researchers have found it useful to examine genetic variations that affect traits like diabetes in Native Americans or high blood pressure in African-Americans. But in the shadow of the Holocaust, scientists in the United States have largely avoided the classification of races as a “futile exercise,” in the words of the population geneticist Luigi Luca Cavalli-Sforza; the very concept of race is a matter of scientific debate.
In “A Troublesome Inheritance: Genes, Race and Human History,” however, Nicholas Wade argues that scientists need to get over their hang-ups and jump into studies of racial difference. “The intellectual barriers erected many years ago to combat racism now stand in the way of studying the recent evolutionary past,” he writes.
Mr. Wade, a longtime science writer for The New York...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...